Why US Put India Back on IP Priority Watch List 2026
Persistent IP shortcomings have landed India back on the US Priority Watch List, as detailed in the freshly unveiled 2026 Special 301 Report from the US Trade Representative. Enforcement lapses and...
Persistent IP shortcomings have landed India back on the US Priority Watch List, as detailed in the freshly unveiled 2026 Special 301 Report from the US Trade Representative. Enforcement lapses and patent delays top the bill of grievances, mirroring long-standing bilateral irritants. India shares the list with IP laggards China, Russia, and Indonesia. Credit is given for bolstering examiner ranks and awareness efforts, though the report deems progress patchy at best. Central to criticisms: India's patent regime, plagued by approval backlogs from rigorous scrutiny and opposition marathons. Pharma firms decry bans on key inventions, hampering market entry. Test data for meds and farm chemicals lacks ironclad protection, inviting exploitation. Enforcement woes compound the issues—fragmented oversight, toothless fines, surging fakes, pirated media, and dodgy software. Trademark cases languish amid subpar probes, and trade secrets float unprotected by law. Amid critiques, India's 2024 patent reforms signal intent to cut delays. The US pledges sustained talks. 'All tools against foul play are in play,' declared USTR's Jamieson Greer. 'Innovators need robust IP,' echoed Rick Switzer. This watch list status invites rigorous US oversight and bilateral pressure. It encapsulates chronic divides in pharma, agrotech, and digital IP—arenas pivotal to US exports—hinting at tougher stances ahead in trade negotiations.